Aerie Pharmaceuticals, Inc.
If you purchased Aerie Pharmaceuticals, Inc. securities and would like to join the action, please click "Join This Action" below.
AERI STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF AERIE PHARMACEUTICALS, INC. IS FAIR TO SHAREHOLDERS
August 24, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to Alcon for $15.25 per share is fair to Aerie shareholders.
The investigation concerns whether Aerie and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Aerie shareholders; (2) determine whether Alcon is underpaying for Aerie; and (3) disclose all material information necessary for Aerie shareholders to adequately assess and value the merger consideration. On behalf of Aerie shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.